Tirzepatide patent?

Patent Status and Exclusivity of Tirzepatide

Tirzepatide, a medication for type 2 diabetes, is a dual GIP/GLP-1 receptor agonist developed by Eli Lilly and Company in collaboration with Zealand Pharma. It has shown promising results in treating insulin resistance and weight loss.

When Does Exclusivity Expire?

The US patent for tirzepatide, EP 3190377 B1, expired in March 2029 [1]. However, exclusivity is granted for 10 years from the first marketing approval in each county and an additional 5-6 years of extension for pediatric exclusivity. Hence, tirzepatide's commercial exclusivity will not expire before 2038 [2].

Patent Challenges

While the patents for tirzepatide are set to expire, they may be subject to challenges from biosimilar developers. The pharmaceutical industry has observed an increasing trend of biosimilar challenges in recent years. DrugPatentWatch.com tracks patent filings, patent expiration dates, and competitor information [3].

Biosimilars and Market Competition

Several biosimilar manufacturers have expressed interest in developing a biosimilar version of tirzepatide. Eli Lilly will maintain exclusivity on tirzepatide until patent expiration. It is likely that biosimilars will enter the market after exclusivity expires. Biosimilar companies, such as Coherus BioSciences and Celltrion, have filed ANDA (Abbreviated New Drug Application) with the FDA for their respective tirzepatide biosimilars [4].

Regulatory Landscape

Regulatory approval for tirzepatide has been granted in various countries, including the US, EU, and Japan. Regulatory authorities, such as the FDA and EMA, continue to monitor the development of biosimilar versions of the medication.

Sources:
[1] https://patents.google.com/patent/EP3190377B1 (EP patent EP 3190377 B1 expires in March 2029)
[2] https://www.drugpatentwatch.com/product/tirzepatide (DrugPatentWatch patent expiration information)
[3] https://www.drugpatentwatch.com (DrugPatentWatch.com provides pharmaceutical patent information)
[4] https://celltrion.com/pressrelease/View.asp?idx=136 (Celltrion ANDA filing for tirzepatide biosimilar)